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Original ArticleDevelopment of a Novel AAV Gene Therapy
Cassette with Improved Safety Features
and Efficacy in a Mouse Model of Rett Syndrome
Kamal K.E. Gadalla,1,2 Thishnapha Vudhironarit,1 Ralph D. Hector,1 Sarah Sinnett,3,4 Noha G. Bahey,1,5
Mark E.S. Bailey,6 Steven J. Gray,3,4,7 and Stuart R. Cobb1
1Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK; 2Pharmacology Department,
Faculty of Medicine, Tanta University, Tanta 31527, Egypt; 3Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; 4Carolina
Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; 5Histology Department, Faculty of Medicine, Tanta
University, Tanta 31527, Egypt; 6School of Life Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK; 7Department
of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USARett syndrome (RTT), caused by loss-of-function mutations
in the MECP2 gene, is a neurological disorder characterized
by severe impairment of motor and cognitive functions. The
aim of this study was to investigate the impact of vector design,
dosage, and delivery route on the efﬁcacy and safety of gene
augmentation therapy in mouse models of RTT. Our results
show that AAV-mediated delivery of MECP2 to Mecp2 null
mice by systemic administration, and utilizing a minimal
endogenous promoter, was associated with a narrow therapeu-
tic window and resulted in liver toxicity at higher doses. Lower
doses of this vector signiﬁcantly extended the survival of mice
lacking MeCP2 or expressing a mutant T158M allele but had
no impact on RTT-like neurological phenotypes. Modifying
vector design by incorporating an extended Mecp2 promoter
and additional regulatory 30 UTR elements signiﬁcantly
reduced hepatic toxicity after systemic administration. More-
over, direct cerebroventricular injection of this vector into
neonatal Mecp2-null mice resulted in high brain transduction
efﬁciency, increased survival and body weight, and an amelio-
ration of RTT-like phenotypes. Our results show that control-
ling levels of MeCP2 expression in the liver is achievable
through modiﬁcation of the expression cassette. However, it
also highlights the importance of achieving high brain trans-
duction to impact the RTT-like phenotypes.Received 24 February 2017; accepted 19 April 2017;
http://dx.doi.org/10.1016/j.omtm.2017.04.007.
Correspondence: Stuart Cobb, Institute of Neuroscience and Psychology, College
of Medical Veterinary and Life Sciences, West Medical Building, Glasgow, G12
8QQ UK.
E-mail: stuart.cobb@glasgow.ac.ukINTRODUCTION
Rett syndrome (RTT; OMIM 312750) is a neurological disorder char-
acterized by a constellation of clinical diagnostic and associated
features and with overt onset occurring several months postnatally.1
Typical RTT is almost exclusively caused by de novo germline muta-
tions in the X-linked gene,MECP22 (as reviewed elsewhere3,4). Several
mouse models of RTT have been generated that harbor Mecp2 dele-
tions5–7 or knocked-in mutations.8–11 Many of these models recapitu-
late the principal features that characterize RTT in humans, although
there are differences that reﬂect the phenotypic variability seen in pa-
tients.12–14 Despite the severity of RTT-like phenotypes, genetic reac-180 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20
This is an open access article under the CC BY license (http://creatitivation of silencedMecp2 in conditional knockout mice resulted in a
robust and enduring reversal of phenotypes.15–17
This inherent reversibility of the phenotype, added to the lack of
obvious targets for pharmacotherapy, makes gene therapy an obvious
therapeutic strategy in RTT. However, there are signiﬁcant challenges
to a gene transfer approach, including the requirement to transduce
sufﬁcient numbers of neurons in the brain16 and the avoidance of
deleterious overexpression.18
Previous attempts at MECP2 gene transfer using AAV9 vectors were
confounded by limited brain transduction efﬁciency and toxicity,19,20
while efﬁcacy in other studies using self-complementary adeno-asso-
ciated virus (AAV) (scAAV)21 may have been compromised by the
use of a construct exceeding the packaging capacity of the vector.
The aim of the present study was to assess the therapeutic impact of
dose, route of administration, and expression cassette design in mice
modeling RTT. Our results show that modiﬁcation of the vector
design by incorporating more regulatory elements is able to reduce
peripheral expression of vector-derived MeCP2 and prevent liver
toxicity. We also show that using the same vector design by direct
brain injection in mouse neonates resulted in higher brain transduc-
tion and improved the RTT-like phenotype.
RESULTS
Dose Escalation with AAV/MECP2 Revealed a Narrow
Therapeutic Window following Systemic Administration
In order to explore the relationship between vector dose and thera-
peutic beneﬁts, we conducted a dose escalation experiment in which17 ª 2017 The Authors.
vecommons.org/licenses/by/4.0/).
Figure 1. Systemic Delivery of the First-Generation
Vector to Mecp2–/y Mice Revealed Therapeutic
Efficacy and a Narrow Therapeutic Window
(A) Kaplan-Meier survival plot for Mecp2/y mice injected
with different doses (1  1011 [n = 10], 1  1012 [n = 8],
and 1  1013 [n = 5] vg per mouse] of first-generation
vector compared to vehicle-treated animals (WT; n = 9,
Mecp2/y; n = 16). The median survival period in
Mecp2/y mice treated with 1  1012 vg per mouse was
significantly higher than that in vehicle-treated controls
(27.14 versus 11.64 weeks; p = 0.001, Mantel-Cox test).
(B and C) Plots showing mean (B) body weight and (C)
aggregate severity scores forMecp2/ymice treated with
1  1011 and 1  1012 vg per mouse or vehicle. Arrows
indicate age at injection; data are presented as mean ±
SEM. (D) Dose-dependent transduction efficiency (Myc-
positive nuclei as a proportion of DAPI-positive nuclei)
across different brain regions. Data are presented as
mean ± SEM (n = 3 mice per group). CA1 indicates hip-
pocampal region CA1.
www.moleculartherapy.organ scAAV2/9 vector was used to deliver a Myc-tagged human
MECP2_e1 cDNA under the control of a short, 229-bp region of
the murineMecp2 endogenous core promoter (MeP229),19,22 herein-
after referred to as the “ﬁrst-generation vector”. Juvenile male
Mecp2/y and wild-type (WT) mice were injected at the age of
4–5 weeks in the tail vein either with vehicle or with 1  1011 (low
dose), 1  1012 (moderate dose), or 1  1013 (high dose) viral ge-
nomes (vg) per mouse (dose range, 1  1013–1  1015 vg/kg). As
expected from previous studies of this knockout line,6,7,15 onset of
RTT-like phenotypic signs in control vehicle-treated Mecp2/y
mice15 was observed from 4 to 5 weeks of age, and severity progres-
sively increased until death or censoring of all mice by 20 weeks of
age (Figures 1A–1C). Mecp2/y mice treated with the low dose were
indistinguishable from vehicle-treatedMecp2/ymice in terms of sur-
vival (median survival = 9.36 weeks versus 11.64 weeks, respectively;
p = 0.2, Mantel-Cox test,) and severity score (Figures 1A and 1C).Molecular Therapy: MethodsHowever, when measured at 11 weeks (the
median survival time for the control vehicle-
treated Mecp2/y mice), the mean body weight
of the treated Mecp2/y mice was signiﬁcantly
(p < 0.05) higher than that of the Mecp2/y
vehicle controls (Figure 1B).
In contrast, Mecp2/y mice treated with the
moderate dose (1  1012) showed signiﬁcantly
increased survival and body weight compared
to the vehicle controls (median survival =
27.3 weeks versus 11.64 weeks; p = 0.001,
Mantel-Cox test [Figure 1A]; p < 0.05 for
mean body weight measured at 11 weeks of
age [Figure 1B]). However, there was no differ-
ence in the RTT-like phenotype severity score at
this dose (Figure 1C). Finally, the cohort
receiving the highest dose showed acute toxicityand lethality at 10–15 days post-injection (Figure 1A). Overall,
vehicle-treated WT mice differed from Mecp2/y cohorts across all
measures (all ps < 0.001).
Patterns of transduction in treated Mecp2/y mice were assessed
within the CNS by anti-Myc antibody immunoﬂuorescence labeling
(Figure S1), which revealed vector-derivedMeCP2 protein expression
distributed in a punctate pattern within cell nuclei corresponding to
that observed for endogenous MeCP2 in WT mice. Samples from
the low-dose cohort revealed low transduction efﬁciencies across
brain regions (0.5% to 1%). The moderate dose resulted in 3%–
5% transduction efﬁciency, whereas the efﬁciency for the high dose
was 10%–22% (Figure 1D).
In order to measure cellular levels of vector-derived MeCP2 relative
to native levels, WT mice were treated with vector as described& Clinical Development Vol. 5 June 2017 181
Figure 2. Intravenous Injection of the First-
Generation Vector Resulted in Pathological Changes
in the Liver
(A–D) Representative H&E-stained liver sections from WT
mice injected with (A) vehicle or (B–D) different doses of
vector. (E) Liver section from a mouse injected intrave-
nously with a GFP control vector, counterstained with DAPI.
(F) Representative H&E-stained liver section from a GFP
vector-treated mouse. Arrows indicate mononuclear cell
infiltration, vacuolation, and/or loss of hepatocytes. Dashed
white line indicates cellular swelling. Scale bars indicate
20 mm. CV, central vein.
Molecular Therapy: Methods & Clinical Developmentearlier. The low and moderate doses were tolerated and had no
observable effect on body weight or phenotypic severity score (Fig-
ures S2A–S2C). However, WT mice treated with the high dose
exhibited the acute toxicity and rapid lethality observed in the
knockout mice (Figures S2A–S2C). Quantiﬁcation of cellular levels
of MeCP2 in mice given this high dose revealed that transduced hip-
pocampal pyramidal cells expressed vector-derived MeCP2 at a
mean level equivalent to 120% of the endogenous level, resulting
in total cellular levels of MeCP2 just over 2-fold higher than normal
for these cells (Figures S2D–S2F).
Systemic Delivery of First-Generation Vector Resulted in Liver
Toxicity
To further investigate toxic effects encountered after systemic injec-
tion of the ﬁrst-generation vector at high doses, levels of vector-
derivedMeCP2 expression were tested in a range of peripheral tissues.
Bio-distribution of the vector genome in different organs was quanti-
ﬁed using qPCR at the end of experiment (Figure S3) and revealed,
along with immunohistochemistry, that the proportion of Myc-pos-
itive cells in the liver was high (Figure S4). Endogenous MeCP2 levels
are known to be much lower in liver cells than in brain neurons23,24
and are typically below the detection threshold for immunohisto-
chemistry using available antibodies (Figure S4A). However, vector-182 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017derived MeCP2 levels in a subset of liver cells
(using anti-Myc-immunolabeling) of treated
WT mice were found to be higher than MeCP2
levels seen in neurons (Figures S4B and S4C)
and were thus20 times higher than levels found
endogenously in such cells. Myc-positive cells
were detected also in the heart, kidney, and other
peripheral tissues in treated Mecp2/y mice (data
not shown).
Histological investigation of liver sections from
mice injected with vehicle or a low dose of the
vector showed a largely normal liver structure
with occasional areas of mononuclear inﬁltration
(Figures 2A and 2B). In contrast, mice injected
with higher doses of the vector showed a dose-
dependent increase in pathological features,including cellular destruction and vacuolation, loss of hepatocytes,
and mononuclear cell inﬁltration (Figures 2C and 2D).
To address whether the observed liver pathology was due to the high
copy number of viral particles per se or was a consequence of MeCP2
overexpression, we injected mice with a vector driving expression of
GFP but otherwise identical to the ﬁrst-generation vector. Despite
detection of widespread GFP expression in the liver (Figure 2E), his-
tological examination of liver sections revealed no evidence of cellular
damage or immune cell inﬁltration (Figure 2F). In addition, no
changes in RTT aggregate severity score were observed with this vec-
tor (data not shown).
Systemic Administration of First-Generation Vector Improves
Survival in Mecp2T158M/y Knockin Mice
An important question for gene transfer in RTT is whether the pres-
ence of endogenous mutant MeCP2 might reduce the therapeutic ef-
fect of vector-derived wild-type MeCP2. Male mice expressing native
MeCP2 tagged with GFP as a fusion protein and harboring the
common RTT-causing p.T158M mutation,9 Mecp2T158M/y, display a
phenotype very similar to that of Mecp2 null mice (Figure S5), but
with somewhat enhanced survival (median survival = 20.3 weeks
and 12.4 weeks, respectively; p = 0.0016, Mantel-Cox test).
Figure 3. Improved Survival and Body Weight of
Mecp2T158M/Y Mice after Systemic Delivery of the First-
Generation Vector
(A) Survival plot for treatedMecp2T158M/ymice. Arrow indicates
age at injection. (B and C) Plots of (B) body weight and C)
aggregate severity score, respectively, for Mecp2T158M/y mice
treated with 1  1012 vg per mouse of first-generation vector
and control groups (Mecp2T158M/y and WT) treated with
vehicle. Data presented as mean ± SEM. (D) Transduction ef-
ficiency in the brain of treated mice (Myc-positive nuclei as a
proportion of DAPI-positive nuclei; n = 3 mice).
www.moleculartherapy.orgIntravenous delivery of a moderate dose (1  1012 vg per mouse) of
the ﬁrst-generation vector to 4- to 5-week-old Mecp2T158M/y mice re-
sulted in signiﬁcantly increased survival (Figure 3A;median survival =
38.3 weeks in vector-treated mice versus 20.3 weeks in vehicle-treated
mice; p = 0.0019, Mantel-Cox test, n = 8–15 per group). There was a
modest increase in body weight in the vector-treated cohort (Fig-
ure 3B; p < 0.05, one-way ANOVA using data at 20 weeks of age).
However, there was no difference in RTT-like aggregate severity score
between groups (Figure 3C), consistent with a low brain transduction
efﬁciency (2%–4%) as revealed by anti-Myc labeling (Figure 3D).
Overall, vehicle-treated WTmice differed fromMecp2T158M/y cohorts
across all measures (all ps < 0.01).
The p.T158M mutation affects the chromatin-binding capacity of
MeCP2, leading to loss of the punctate element of MeCP2 labeling
in the nucleus (Figure 4A).9 Immunolabeling of hippocampal
neurons from treated Mecp2T158M/y mice showed WT patterns of
MeCP2 expression, with restored localization to DAPI bright spots,
only in transduced (Myc-positive) cells (Figure 4B). This is consistent
with vector-derived MeCP2 being able to localize normally to heter-
ochomatin, despite the presence of mutant endogenous MeCP2 pro-
tein within the same nucleus.
Development of a Second-Generation Vector that Reduced Liver
Toxicity after Systemic Administration
In light of the data described earlier, it was evident that a higher AAV
vector dose is required to achieve therapeutically relevant levels ofMolecular Therapy: Methbrain transduction after systemic delivery. However,
severe toxicity after delivery of high doses of our
ﬁrst-generation cassette necessitated a new design.
We tested a range of modiﬁcations to the expression
cassette and capsid that were predicted to result in
lower cellular expression levels and/or reduce liver
tropism. This included the use of expression cas-
settes utilizing (1) an alternative, compact, and, pre-
sumably, weaker JeT promoter25; (2) a short syn-
thetic polyadenylation (SpA) signal (Figure S6A)26;
and (3) the original ﬁrst-generation expression
cassette packaged in a scAAV9.47 capsid, which
emerged from an in vivo screen for liver de-targeted
capsid sequences relative to AAV9.27,28 Systemic in-jection of these vectors at the moderate dose (1 1012 vg per mouse)
into 4- to 5-week-old Mecp2/y mice resulted in signiﬁcantly
extended survival and improved body weight, but there was no
impact on the RTT-like aggregate severity score (Figure S6B). In sum-
mary, none of these modiﬁcations resulted in any signiﬁcant im-
provements over the ﬁrst-generation vector (p > 0.05 for all measures,
ANOVA and Mantel-Cox tests). Importantly, these modiﬁed vectors
all caused the development of liver pathology similar to that observed
with the ﬁrst-generation vector (as previously shown in Figure 2;
Figure S6C).
The rationale for using an endogenous Mecp2 core promoter frag-
ment (MeP229) in the ﬁrst-generation vector was that it had been
shown largely to recapitulate the endogenous tissue-level pattern
of MeCP2 expression.22 However, this core promoter fragment is
missing a number of predicted upstream regulatory elements that
may be important in cell-type-speciﬁc regulation of MeCP2 expres-
sion.29–31 Therefore, we designed a second-generation vector in
which we used an extended promoter fragment (MeP426) incorpo-
rating additional promoter regulatory elements and a putative
silencer element (Figure S7). We predicted that this might better
enable the regulation of vector-derived MeCP2 levels in transduced
cells. In addition to the extended promoter, we also incorporated a
novel 30 UTR, consisting of a fragment of the endogenous MECP2
30 UTR together with a selected panel of binding sites for microRNAs
(miRNAs) known to be involved in regulation of Mecp232–35
(Figure S7).ods & Clinical Development Vol. 5 June 2017 183
Figure 4. Nuclear Localization of MeCP2 in
Untreated and Treated Mecp2T158M/Y Mice
Representative confocal images of the CA1 region of
the hippocampus. (A) Endogenous MeCP2 exhibits
heterochromatin-enriched localization in WT nuclei, while
GFP-tagged MeCP2 exhibits decreased heterochromatin
localization (i.e., more diffuse labeling) in nuclei from
Mecp2T158M/y mice. (B) Images demonstrating hetero-
chromatin-enriched localization of vector-derived MeCP2
in nuclei of transduced cells inMecp2T158M/ymice treated
with the first-generation vector. White arrows indicate
transduced cells (Myc-positive). Scale bars indicate
20 mm.
Molecular Therapy: Methods & Clinical DevelopmentIn order to test the therapeutic efﬁcacy of the second-generation vec-
tor, a moderate dose (1  1012 vg per mouse) was injected intrave-
nously into 4- to 5-week-old Mecp2/y mice. There was a signiﬁcant
extension of survival in the vector-treated mice compared to the
vehicle-treated mice (median survival = 29.9 weeks and 11.6 weeks,
respectively; p < 0.0001, Mantel-Cox; Figure 5B). There was also sig-
niﬁcant improvement in body weight at the age of 11 weeks (p < 0.05,
one-way ANOVA, with Tukey’s post hoc pairwise comparison test;
Figure 5C). In contrast, there was no effect on RTT-like aggregate
severity score (Figure 5D). The second-generation vector, thus,
showed no therapeutic advantages over the ﬁrst-generation vector
after systemic delivery (Figures 5B–5D). Again, vehicle-treated
WT mice differed from Mecp2/y cohorts across all measures (all
p < 0.001). In order to compare this vector head-to-head with the
ﬁrst-generation vector in terms of liver safety, mice were injected
intravenously with either the ﬁrst- or the second-generation vector
at a dose of 1  1012 vg per mouse. These mice were sacriﬁced after
30 days, and tissues were analyzed for vector-derived MeCP2 expres-
sion (using anti-Myc tag antibody) and signs of liver pathology (Fig-
ure 6). There was no signiﬁcant difference in transduction efﬁciency
between vector constructs (Figure 6B), but cellular levels of vector-
derived MeCP2 (anti-Myc) in mice treated with ﬁrst-generation
vector were signiﬁcantly higher than those in mice treated with sec-
ond-generation vector (Figure 6C; p < 0.001, unpaired t test). Analysis
of the distribution of cellular MeCP2 expression levels in transduced
cells showed that MeCP2 expression was more tightly regulated in
mice injected with the second-generation vector (Figure 6D), with
fewer cells exhibiting very high expression levels. Moreover, there
was none of the disrupted hepatic architecture or vacuolation previ-
ously observed with the ﬁrst-generation vector (Figure 6E). The den-
sity of inﬂammatory foci was signiﬁcantly higher in liver samples
from mice injected with ﬁrst-generation vector than from those in-
jected with the second-generation vector (Figure 6F).
Neonatal Cerebroventricular Injection of the Second-Generation
Vector Improved the RTT-like Aggregate Severity Score
The lack of impact on the phenotype after systemic administration is
consistent with the low brain transduction efﬁciencies observed, as it184 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20has been established that phenotype severity and degree of improve-
ment after gene restoration correlate with the proportion of MeCP2-
expressing cells in the brain.16 Therefore, we decided to test the
second-generation vector by direct cerebroventricular injection in
mouse neonates, a delivery route that is known to afford widespread
transgene expression.19 When delivered at a dose of 1  1011 vg per
mouse (Figure 7A), there was a pronounced extension in the survival
of Mecp2/y mice treated with the second-generation vector in
comparison to vehicle-treated mice (median survival = 38.5 and
12.4 weeks, respectively; p < 0.0001, Mantel-Cox test; Figure 7B).
While there was a negligible effect of vector on body weight (Fig-
ure 7C), an important observation was the clear improvement in
the RTT-like aggregate severity score compared to that of vehicle-
treated Mecp2-null mice (Figure 7D; p < 0.01 at 11 weeks, one-way
ANOVA, with Tukey post hoc pairwise comparison). Vector-derived
MeCP2 (revealed by anti-Myc tag immunolabeling) was detectable in
all brain regions, with transduction efﬁciencies across brain regions
ranging from 10%–40% (Figures 7E and 7F). Distribution analysis
revealed that the modal cellular MeCP2 level in transduced cells in
cortex was approximately twice that of endogenous MeCP2 (consis-
tent with a vector-derived expression level equal to the endogenous
level), with some cells expressing higher levels of vector-derived
MeCP2 (Figure 7G).
DISCUSSION
The reversal of a wide range of RTT-like phenotypes in mice
following the delayed unsilencing of Mecp2 provides a strong ratio-
nale for gene transfer as a therapeutic strategy in RTT.15,16 There
are likely to be a variety of barriers to translational success that will
need to be identiﬁed and addressed in order to secure optimal out-
comes in human clinical trials. In the present study, we identiﬁed
particular challenges associated with the systemic delivery of
aMECP2-bearing gene therapy vector in terms of a narrow therapeu-
tic window driven by low brain transduction efﬁciency and the
appearance of peripheral overexpression toxicity upon further dose
escalation. However, peripheral overexpression can be reduced by
reﬁning the cassette design. We show that direct brain delivery of vec-
tor in neonatal mice can achieve therapeutically relevant levels of17
Figure 5. Therapeutic Efficacy of Second-
Generation Vector after Systemic Delivery to
Mecp2–/y Mice
(A) Design features of our second-generation vector
summarized (see Results and Figure S7 for details). (B)
Survival plot forMecp2/ymice treated intravenously with
1  1012 vg per mouse of the second-generation vector
(median survival = 29.9 weeks) or an identical dose of
first-generation vector (median survival = 27.1 weeks) or
vehicle (median survival = 11.6 weeks). Arrow indicates
age at injection. (C and D) Plots showing (C) mean body
weight and (D) aggregate severity scores, respectively, of
Mecp2/y mice treated as in (B). See also Figure S7.
www.moleculartherapy.orgtransduction that result in phenotype amelioration. We also show
that the vector has similar effectiveness in mice expressing the most
common RTT-causing mutation, suggesting that the presence of
existing mutant forms of MeCP2 is unlikely to be an obstacle to trans-
lational success. These results are consistent with experiments
in transgenic mice expressing both mutant and WT forms of the
protein.36
Recent attempts to deliver MECP2 exogenously in mouse models of
RTT used widely varying vector doses but are difﬁcult to compare
based on additional differences in cassette design and other variables,
including viral production, dosing protocol, and phenotype mea-
sures.19–21 In the present study, we used our previously published
cassette design (human MECP2_e1, under the control of a MeP229
core promoter fragment)19 to directly investigate the effect of dose
in terms of efﬁcacy and safety. A notable ﬁnding was the overall
lack of efﬁcacy across the range of doses tested in terms of an effect
on RTT-like phenotype severity score. This is not due to such pheno-
types being inherently resistant to reversal15,16 but is instead most
likely explained by the low levels of brain transgene expression af-
forded by this route of delivery. In contrast to the phenotype severity
score, there was a clear dose-response relationship for survival, with
the intermediate dose causing a modest increase in mean body weight
and a signiﬁcant extension in survival. It is not clear whether the sur-
vival and body weight effects are due to sufﬁcient (if low) transduction
levels in critical brain regions or to expression ofMeCP2 in peripheral
tissues relevant to mortality. Recent evidence suggests that MeCP2
levels in peripheral tissues can subtly affect body weight,23 and it is
possible that this may indirectly affect survival measures, as we are
obliged to use the acute loss of body weight as an endpoint criterion.
However, there was a clear divergence in survival between the 1011-
and 1012-vg doses without overt differences in mean body weight
between groups (Figure 1). Another potential explanation is that we
were underestimating levels of transduction efﬁciency related to sur-
vival, based on the sensitivity of our immunohistochemical detection.
However, vector biodistribution validation using qPCR was consis-
tent with our measurements, conﬁrming very modest transduction
efﬁciencies following systemic delivery. Only the highest dose testedMolecuproduced appreciable levels of brain transduction (>10%–20%),
and, unfortunately, the severe liver pathology and lethality associated
with this dose precluded assessment of the potential for brain-speciﬁc
therapeutic effects in this situation. Liver cells normally express rela-
tively low levels of MeCP2 compared to neurons,23 and identical
doses of a GFP-expressing vector were not toxic, so the dose-depen-
dent liver pathology is likely to be attributed to the overexpression of
vector-derived MeCP2. The difference in the severity score observed
in WT mice treated with the moderate dose (which showed no
apparent toxicity) and with the high dose (which showed high levels
of lethality) can potentially be explained in terms of the cellular levels
of MeCP2 that can be tolerated by liver cells—this tolerability
threshold may lie between the levels of MeCP2 achieved by the two
vector doses.
Previous preclinical RTT gene therapy studies19–21 have focused on
using the Mecp2/y model to screen for vector efﬁcacy and potential
toxicity. However, the presence of mutant endogenous MeCP2 could
potentially produce a quasi-dominant negative action on the vector-
derived MeCP2. We have shown here that, although this knockin
line9 exhibits RTT-like phenotype severity scores similar to those
observed in Mecp2/y mice, it also exhibits prolonged survival, thus
indicating that the mutant allele may produce MeCP2 with some
residual function. Interestingly, AAV-mediated systemic delivery of
MECP2 to these mice resulted in a therapeutic effect similar to that
achieved in the Mecp2/y mice treated with the same vector dose.
Therefore, we conclude that presence of the mutant protein does
not impede the functionality of vector-derived MeCP2. This ﬁnding
supports the potential translational application of augmentation
gene therapy in patients with missense MECP2 mutations.
Our initial attempts to lower toxic MeCP2 expression and/or reduce
liver tropism involved modiﬁcations to the expression cassette and
capsid. However, the use of putative weaker synthetic promoters
and polyadenylation signals was not sufﬁcient to avoid liver toxicity.
Surprisingly, the use of an AAV9.47 capsid, which is purported to de-
target the liver relative to AAV9,27,28 resulted in liver pathology
similar to that seen with AAV9. Therefore, we focused efforts on alar Therapy: Methods & Clinical Development Vol. 5 June 2017 185
Figure 6. Reduced Expression of Vector-Derived MeCP2 in the Livers of Mice Treated with Second-Generation Vector
(A) Flattened confocal stack images from livers of mice 1 month after being injected intravenously at 5 weeks of age with the second-generation vector or first-generation
vector at 1  1012 vg per mouse; confocal settings were the same in each case. Tissues were immunolabeled with anti-Myc and DAPI nuclear stain. Arrows indicate
transduced cells (Myc-positive), and arrowheads indicate non-transduced cells. (B) Transduction efficiencies in the liver for both vectors. (C) Quantification of cellular levels of
vector-derived MeCP2 measured as anti-Myc immunofluorescence in transduced cells in the liver (n = 3 mice, 1,400 transduced cells). Data are presented as mean ± SEM.
(D) Frequency distribution of cellular levels of vector-derived MeCP2 in the liver, measured as in (C). (E) Liver sections stained with H&E showing vacuolation of hepatocytes
(arrows) and sites of mononuclear cell infiltration (dashed circles). CV, central vein. White scale bar indicates 20 mm. (F) Quantification of density of inflammatory foci in the
livers of treated mice (n = 3 per group). Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
Molecular Therapy: Methods & Clinical Developmentsecond-generation vector, whose design was based on the inclusion of
endogenous regulatory elements that may better regulate levels of
vector-derivedMeCP2 in transduced cells. This included the incorpo-186 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20ration of an extended endogenous promoter and an endogenous
30 UTR fragment. Studies analyzing the well-conserved human
MECP2 and mouse Mecp2 promoter regions indicated the presence17
Figure 7. Direct Brain Delivery of Second-
Generation Vector to Neonatal Mecp2–/y Mice
Revealed Therapeutic Efficacy
(A) Experimental design. KO, knockout. (B) Survival plot
showing extended survival of neonatally treatedMecp2/y
mice (median survival = 38.6 weeks; p < 0.0001, Mantel-
Cox test) compared with vehicle-treated animals (median
survival = 12.4 weeks). (C and D) Plots showing mean (C)
body weight and (D) aggregate severity scores, respec-
tively, for the mice shown in (B). (E) Representative
confocal images from the cortex of injected wild-type
mice.White arrows indicate transduced cells; arrowheads
indicate non-transduced cells; scale bars indicate 20 mm.
(F) Graph showing transduction efficiency in different brain
regions (n = 3 mice). (G) Frequency distribution of MeCP2
levels in transduced and non-transduced (“native”) cells in
the mouse cortex (n = 3 mice; 954 transduced cells) data
presented as mean ± SEM.
www.moleculartherapy.orgof a number of putative regulatory elements within a 1-kb window
immediately upstream of the transcription start site.29–31 Conse-
quently, our extended endogenous promoter (426 bp) in the sec-
ond-generation vector comprised a putative silencer element at posi-
tion 274 to 335, with respect to the RefSeq transcription start site
(Figure S7).
An endogenous 30 UTR was also incorporated, containing the distal
MECP2 polyadenylation signal and a number of clustered putative
regulatory elements.37–39 In addition, we performed an analysis ofMolecular Therapy: MethodsmiRNA binding sites in the 30 UTR of
MECP2, using a number of bioinformatic
tools,40–42 and incorporated a compact
sequence containing the binding sites of three
highly conserved miRNAs known to be
involved in regulation of MeCP2 in the brain;
miR-22,32 miR-19,33 and miR-132.34 Com-
bined, these modiﬁcations signiﬁcantly reduced
MeCP2 expression in the liver, with subsequent
reduction of the hepatotoxicity encountered
with the ﬁrst-generation vector. The relative
importance of different modiﬁcations (elements
within the extended promoter and novel 30
UTR) was not investigated. However, the efﬁ-
cacy of both vectors after systemic injection of
moderate doses was not signiﬁcantly different.
The important advantage of the second-genera-
tion vector is the lack of prominent liver pathol-
ogy at a dose that provides some therapeutic
beneﬁt (i.e., 1  1012 vg per mouse). The
improved survival after systemic injection,
despite low brain transduction efﬁciency, could
be due to restoration of MeCP2 levels in sufﬁ-
ciently numerous critical cells in the brain or
due to restoration in important peripheral tis-sues. Targeting more cells in the brain through direct brain injection
in mouse neonates, along with potentially greater impact via earlier
intervention, led to pronounced survival enhancement at a dose
(1  1011 vg per mouse) approximately equivalent to the 1012 sys-
temic dose. Delivery by this direct brain injection route was associated
with an improvement in body weight but, importantly, also with an
improvement in RTT-like phenotype score. The improvement was
not as profound as that reported in genetic reversal experiments,16
and this is likely to be due to the combined effects of (1) the relative
inefﬁciency of MeCP2 re-expression across the brain (10%–40%),& Clinical Development Vol. 5 June 2017 187
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possible deleterious counteracting effects of overexpressing MeCP2
in a proportion of transduced cells. Analysis of MeCP2 levels, indeed,
indicates a signiﬁcant pool of cells overexpressing MeCP2, presum-
ably transduced with multiple copies of vector delivering MECP2.
This may also account for the slightly elevated severity score in vec-
tor-treated WTmice (Figure 7D) in the form of mild hindlimb clasp-
ing. We cannot rule out very subtle consequences of MeCP2 overex-
pression that may be revealed by ﬁne-grained behavioral testing.
Overall, the proof-of-concept experiments involving direct brain de-
livery in neonatal mice suggest that, if transduction efﬁciency across
the brain can reach sufﬁciently high levels, then a behavioral improve-
ment is conferred by this vector design.
Conclusions
The results of the present study highlight the challenges associated
with both systemic and direct brain delivery ofMECP2. The ﬁndings
suggest that achieving widespread brain expression, while at the same
time maintaining cell-type appropriate control of MeCP2 levels, will
be essential requirements for the successful development of a transla-
tional therapy. The development of expression cassettes capable of
producing effective and sub-toxic levels of MeCP2 may overcome
issues of cellular overexpression and enable direct delivery via the
cerebrospinal ﬂuid compartment. While AAV9 appears to be insufﬁ-
ciently efﬁcient in terms of brain transduction after systemic delivery
of MECP2 to achieve the desired therapeutic beneﬁt, combining the
safer second-generation cassette together with capsids with improved
brain penetrance43 may effectively pair effective CNS gene transfer
with safe levels of peripheral MeCP2 transgene expression. Such a
combination would hold enhanced translational promise.
MATERIALS AND METHODS
Animals
All experiments were carried out in accordance with the European
Communities Council Directive (86/609/EEC) and with the terms
of a project license under the UK Scientiﬁc Procedures Act (1986).
TheMecp2 null,Mecp2tm1.1Bird, andMecp2T158M mice, originally pro-
vided as a kind gift from Professor Adrian Bird, were maintained on a
C57BL/6 background. Animals were maintained on 12-hr:12-hr light/
dark cycles with free access to normal mouse food. Mice were geno-
typed as described previously.9,15
Viral Vector Preparation
Recombinant AAV vector particles were generated at the University
of North Carolina (UNC) Gene Therapy Center Vector Core facility.
The scAAV particles (AAV2 ITR [inverted terminal repeat]-ﬂanked
genomes packaged into AAV9 or AAV9.47 serotype capsids) were
produced from suspension HEK293 cells transfected using polyethy-
leneimine (Polysciences) with helper plasmids (pXX6-80 and pGSK2/
9) and a plasmid containing the appropriate ITR-ﬂanked transgene
construct. All MeCP2-expressing constructs utilized the human
MECP2_e1 coding region with a C-terminal Myc epitope tag unless
stated otherwise. Virus production was performed as previously
described,44 and the vectors were prepared in a ﬁnal formulation of188 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20high-salt PBS (containing 350 mmol/L total NaCl) supplemented
with 5% sorbitol.
scAAV Vector Injection and Mouse Phenotyping
Frozen scAAV9 viral particle aliquots were thawed and diluted to
100 mL in PBS/350 mmol/L NaCl containing 5% sorbitol. Control in-
jections were made using the same diluent lacking vector (“vehicle
control”). For direct brain injection into mouse neonates, littermates
were sexed at birth, and direct bilateral injections of virus (3 mL per
site) were delivered into the neuropil of unanesthetized males at post-
natal day (P)0–P3, as described previously.19 The injected pups were
returned to the home cage containing their non-injected female litter-
mates. Genotyping was carried out at 3 weeks, at which time pheno-
typing was initiated. For injection into juvenile male mice, injections
were made via the tail vein at 4–5 weeks of age. Following injection, all
mice were weighed weekly. Phenotyping was carried out, blind to ge-
notype and treatment, twice a week. Mice were scored on an aggregate
severity scale using an established protocol (mice were scored for
RTT-like phenotypes comprising mobility, gait, breathing, hindlimb
clasping, tremor, and general condition).15,16,19,21 For survival anal-
ysis, mice were censored after natural death or if body weight losses
exceeded 20% of peak body weight.
Vector Biodistribution Analysis
For these analyses, mice were sacriﬁced, blood was collected transcar-
dially, andorganswere harvested forDNApuriﬁcation.GenomicDNA
was recovered from tissues using the DNeasy Blood and Tissue Kit
(QIAGEN). A Qiacube (QIAGEN) was used to carry out automated
puriﬁcations. Genomic qPCR reactions and analysis were performed
on a Roche Lightcycler 480, following the manufacturer’s instructions.
For the quantiﬁcation of vector biodistribution, the amount of vector
genome present in each sample was standardized against an amplicon
froma single-copymouse gene, Lmnb2, ampliﬁed fromgenomicDNA.
Lmnb2 primers and “universal” MECP2 primers (that amplify mouse
and human MECP2) were published previously.19,45
Immunohistochemistry
Mice were anesthetized with pentobarbitone (50 mg, intraperitone-
ally) and transcardially perfused with 4% paraformaldehyde (0.1
mol/L PBS). A vibrating microtome (Leica VT1200) was used to
obtain 80-mm sections of brain, spinal cord, and liver. Sections were
dehydrated by incubation in 50% ethanol in distilled water (v/v) for
30 min and then were washed three times in 0.3 mol/L PBS, followed
by incubation in 10 mM sodium citrate (pH 6, 85C, 30 min) for an-
tigen retrieval. Sections were then incubated in the blocking solution
(5% normal goat serum in 0.3mol/L PBS with 0.3% Triton X-100)
for 1 hr at room temperature. Samples then were incubated for
48 hr on a shaker at 4C with the following primary antibodies: rabbit
anti-Myc (Abcam, ab9106), mouse monoclonal anti-MeCP2 (Sigma,
WH0004204M1), and chicken anti-GFP (Abcam, ab13970). The pri-
mary antibodies were then washed off (3 0.3 mol/L PBST), and sec-
ondary antibodies were applied to the sections overnight at 4C: Alexa
Fluor 488 goat anti-mouse/rabbit (Invitrogen; 1/500), Alexa Fluor
546 goat anti-mouse/rabbit (Invitrogen; 1/500), Alexa Fluor 649,17
www.moleculartherapy.orggoat anti-mouse (Jackson ImmunoResearch Laboratories, 112-495-
003JIR). Finally, sections were incubated with DAPI nuclear stain
(Sigma; 1/1,000) for 30 min at room temperature before mounting
with Vectashield (Vector Laboratories).
H&E Staining
Liver samples were rinsed with 0.1 mol/L PBS and then dehydrated
through ascending grades of ethanol, and they were then cleared in
amyl acetate using an automated tissue processor. Specimens were
embedded in Paraplast, and sections (10 mm thick) were collected
on APES (aminopropyltriethoxysilane)-coated slides and dried over-
night in the oven at 37C. Sections were then deparafﬁnized through
two changes of Histo-Clear (Agar Scientiﬁc) for 15 min and rehy-
drated through descending grades of alcohol (100%, 90%, and
70%). The sections were stained with Mayer’s hematoxylin for
8 min and then rinsed using tap water. The nuclei were stained
blue by placing the slides into Scott’s solution for 1 min and were
then rinsed using tap water. Sections were then stained with 1% eosin
for 2 min and washed by water. Finally, the sections were dehydrated
through ascending grades of alcohol and Histo-Clear before being
mounted with DPX. Images were captured using an AxioCam MRc
(Zeiss) mounted on a light microscope (Zeiss).
Image Analysis
Analysis of expression patterns, transduction efﬁciency, and quantiﬁ-
cation of vector-derivedMeCP2 levelswithin nuclei was carried out on
image stacks captured using aZeiss LSM710 or ZeissAxiovert LSM510
laser confocal microscope (Zeiss). The z series were taken at 1-mm in-
tervals through the section of interest using a 40 objective. To ac-
count for antibodies’ penetrability, stack images were taken close to
the surface of sections to a maximum depth of 20 mm. To estimate
transduction efﬁciency, images were captured as described earlier,
and the ratio of Myc-immunopositive nuclei to DAPI-stained nuclei
was calculated for random ﬁelds (n = 12 images per region:4 images
from each of three mice) from sections of hippocampus (CA1 region),
layer 5 of primary motor cortex, thalamus, hypothalamus, brain stem,
and striatum. To quantify levels of vector-derived MeCP2 per nucleus
inWTmice, confocal stacks (20 mm thick) were obtained as described
earlier, and ImageJ software (http://rsbweb.nih.gov/ij/) was used to
determine mean MeCP2-channel ﬂuorescence intensity within trans-
duced (Myc +ve) and non-transduced (Myc ve) cells. Fluorescence
in the DAPI channel was used to deﬁne the nuclear boundary.
Statistical Analysis
Tests for differences between treatment groups were carried out in
GraphPad PRISM using one-way ANOVA, Student’s t test, and the
Mantel-Cox test (survival curves), as appropriate. p < 0.05 was used
to deﬁne statistical signiﬁcance. In multi-group comparisons, multi-
ple testing correction for pairwise tests among groups was applied
using Tukey’s post hoc analysis.
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